Literature DB >> 28518105

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT.

Sabrina H L Hoffmann1, Andreas Maurer1, Dorothea I Reck1, Gerald Reischl1, Bernd J Pichler1, Manfred Kneilling2, Christoph M Griessinger3.   

Abstract

This protocol illustrates the production of 64Cu and the chelator conjugation/radiolabeling of a monoclonal antibody (mAb) followed by murine lymphocyte cell culture and 64Cu-antibody receptor targeting of the cells. In vitro evaluation of the radiolabel and non-invasive in vivo cell tracking in an animal model of an airway delayed-type hypersensitivity reaction (DTHR) by PET/CT are described. In detail, the conjugation of a mAb with the chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) is shown. Following the production of radioactive 64Cu, radiolabeling of the DOTA-conjugated mAb is described. Next, the expansion of chicken ovalbumin (cOVA)-specific CD4+ interferon (IFN)-γ-producing T helper cells (cOVA-TH1) and the subsequent radiolabeling of the cOVA-TH1 cells are depicted. Various in vitro techniques are presented to evaluate the effects of 64Cu-radiolabeling on the cells, such as the determination of cell viability by trypan blue exclusion, the staining for apoptosis with Annexin V for flow cytometry, and the assessment of functionality by IFN-γ enzyme-linked immunosorbent assay (ELISA). Furthermore, the determination of the radioactive uptake into the cells and the labeling stability are described in detail. This protocol further describes how to perform cell tracking studies in an animal model for an airway DTHR and, therefore, the induction of cOVA-induced acute airway DHTR in BALB/c mice is included. Finally, a robust PET/CT workflow including image acquisition, reconstruction, and analysis is presented. The 64Cu-antibody receptor targeting approach with subsequent receptor internalization provides high specificity and stability, reduced cellular toxicity, and low efflux rates compared to common PET-tracers for cell labeling, e.g.64Cu-pyruvaldehyde bis(N4-methylthiosemicarbazone) (64Cu-PTSM). Finally, our approach enables non-invasive in vivo cell tracking by PET/CT with an optimal signal-to-background ratio for 48 h. This experimental approach can be transferred to different animal models and cell types with membrane-bound receptors that are internalized.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28518105      PMCID: PMC5565140          DOI: 10.3791/55270

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  26 in total

Review 1.  Deep tissue two-photon microscopy.

Authors:  Fritjof Helmchen; Winfried Denk
Journal:  Nat Methods       Date:  2005-12       Impact factor: 28.547

Review 2.  Antibodies and antimatter: the resurgence of immuno-PET.

Authors:  Anna M Wu
Journal:  J Nucl Med       Date:  2008-12-17       Impact factor: 10.057

3.  Mouse Naïve CD4+ T Cell Isolation and In vitro Differentiation into T Cell Subsets.

Authors:  Stephanie Flaherty; Joseph M Reynolds
Journal:  J Vis Exp       Date:  2015-04-16       Impact factor: 1.355

4.  Isolation and th17 differentiation of naïve CD4 T lymphocytes.

Authors:  Simone K Bedoya; Tenisha D Wilson; Erin L Collins; Kenneth Lau; Joseph Larkin
Journal:  J Vis Exp       Date:  2013-09-26       Impact factor: 1.355

5.  In vivo tracking of macrophage activated killer cells to sites of metastatic ovarian carcinoma.

Authors:  D Ritchie; L Mileshkin; D Wall; J Bartholeyns; M Thompson; J Coverdale; E Lau; J Wong; P Eu; R J Hicks; H M Prince
Journal:  Cancer Immunol Immunother       Date:  2006-05-30       Impact factor: 6.968

6.  64Cu antibody-targeting of the T-cell receptor and subsequent internalization enables in vivo tracking of lymphocytes by PET.

Authors:  Christoph M Griessinger; Andreas Maurer; Christian Kesenheimer; Rainer Kehlbach; Gerald Reischl; Walter Ehrlichmann; Daniel Bukala; Maren Harant; Funda Cay; Jürgen Brück; Renate Nordin; Ursula Kohlhofer; Hans-Georg Rammensee; Leticia Quintanilla-Martinez; Martin Schaller; Martin Röcken; Bernd J Pichler; Manfred Kneilling
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-13       Impact factor: 11.205

7.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Authors:  James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

8.  An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy.

Authors:  Richard Tavaré; Helena Escuin-Ordinas; Stephen Mok; Melissa N McCracken; Kirstin A Zettlitz; Felix B Salazar; Owen N Witte; Antoni Ribas; Anna M Wu
Journal:  Cancer Res       Date:  2015-11-16       Impact factor: 12.701

Review 9.  Adoptive immunotherapy of cancer using CD4(+) T cells.

Authors:  Pawel Muranski; Nicholas P Restifo
Journal:  Curr Opin Immunol       Date:  2009-03-13       Impact factor: 7.486

10.  Chances and pitfalls of chemical cross-linking with amine-reactive N-hydroxysuccinimide esters.

Authors:  Stefan Kalkhof; Andrea Sinz
Journal:  Anal Bioanal Chem       Date:  2008-09       Impact factor: 4.142

View more
  2 in total

Review 1.  Radionuclide Imaging of Cytotoxic Immune Cell Responses to Anti-Cancer Immunotherapy.

Authors:  Louis Lauwerys; Evelien Smits; Tim Van den Wyngaert; Filipe Elvas
Journal:  Biomedicines       Date:  2022-05-05

2.  Visualization and quantification of in vivo homing kinetics of myeloid-derived suppressor cells in primary and metastatic cancer.

Authors:  Sabrina H L Hoffmann; Dorothea I Reck; Andreas Maurer; Birgit Fehrenbacher; Jaclyn E Sceneay; Marilena Poxleitner; Hasan H Öz; Walter Ehrlichmann; Gerald Reischl; Kerstin Fuchs; Martin Schaller; Dominik Hartl; Manfred Kneilling; Andreas Möller; Bernd J Pichler; Christoph M Griessinger
Journal:  Theranostics       Date:  2019-08-12       Impact factor: 11.556

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.